1st july 2008

New Product Announcement
Postinor®-X

Bayer Schering Pharma is proud to announce the availability of the first one tablet emergency
contraceptive, Postinor®-X as of 1st September 2008.
Postinor®-X contains 1.5mg of levonorgestrel and is indicated for use within 72 hours of
unprotected intercourse. It should only be used as an emergency measure. Women who present
for repeated courses of emergency contraception should seek advice to consider long-term
methods of contraception.1
Postinor®-X’s convenient one tablet regimen eliminates confusion, and efficacy based on
compliance to take a second tablet will no longer be a concern. Efficacy results also show, that the
one tablet regimen appears to be more effective than the two tablet regimen taken twelve hours
apart.1
With added benefits that accompany the one tablet, we anticipate that over time, Postinor®-X may
replace all two tablet versions of the emergency contraceptive as the new gold standard.
Both Healthcare Professionals and Consumers will be advised of the availability of Postinor®-X
from 1st September 2008. You may therefore expect consumers to come in requesting a one tablet
emergency contraceptive. We thus invite you to place your orders with wholesalers to ensure of
availability.
NB: Due to the introduction of Postinor-1, Postinor-2 will be phased out progressively until existing
stock is exhausted.
Yours faithfully
Bayer Schering Pharma
Paul Tobolov
Senior Product Manager
Reference: 1. Approved Postinor-1 Product Information.
Postinor-1 Dispensing Information
Postinor-1: 1.5mg Levonorgestrel. Indications: Oral emergency contraception for use within 72 hours of unprotected intercourse.
Women who present for repeated courses of emergency contraception should be advised to consider long-term methods of
contraception. Contraindications: Should not be given to pregnant women or children. Unexplained vaginal bleeding, current breast
cancer, hypersensitivity to any of the ingredients of the preparation. Precautions: Severe hypertension (BP>180+/110+), diabetes
mellitus with nephropathy, retinopathy, neuropathy or vascular disease, ischaemic heart disease, stroke, or a past history of breast
cancer. Severe hepatic dysfunction. Others: Refer to full Product Information. Interactions: Barbiturates, phenytoin, carbamazepine,
herbal medicines containing hypericum perforatum (St John’s Wort), rifampicin, ritinovir, rifabutin, griseofulvin. Others: Refer to full
Product Information. Adverse Events: Fatigue, nausea, vomiting, diarrhoea, abdominal pain, dizziness, headache, breast tenderness,
menstrual disturbances. Others: Refer to full Product Information. Dosage: One 1.5mg tablet to be taken as soon as possible (and no
later than 72 hours) after unprotected sex. PLEASE REVIEW PRODUCT INFORMATION BEFORE DISPENCING. Full Product
Information is available on request from Bayer Australia Limited, ABN 22 000 138 714, 875 Pacific Highway, Pymble, NSW
2073.


Postinor-1 Support Material
Fax Back Form

I would like to receive:
(please tick)
{ Postinor-1 Product Information
{ Postinor-1 Pharmacy Question Pad
{ Postinor-1 Patient Leaflet Pad
{ Postinor-1 Detail Aid
NB. All support materials above can also be downloaded from:

(Password: ectablet)
Pharmacist name:
____________________________________________________________________ Pharmacy address: ____________________________________________________________________ ____________________________________________________________________ ____________________________________________________________________ ____________________________________________________________________ Pharmacist Signature: ____________________________________________________________________

Source: http://ozdocit.org/pipermail/carpa/attachments/20080815/bc7f8a96/Bayer_Postinor-1_Pharmacist_letter_11Aug08complete.pdf